Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Context Therapeutics Inc. Common Stock

CNTX

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Last trade $0.1729
Day change +$0.007 (+4.22%)
Day range $0.153 – $0.184
Volume 1,667,247
Market cap $15M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$15.62M
Price / earnings
—
Price / book
0.5×
Price / sales
—
EV / sales
—
EV / EBITDA
0.41×

Profitability

Earnings per share
-$0.48
Return on assets
-120.12%
Return on equity
-141.55%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.59×
Quick ratio
6.59×
Cash ratio
6.26×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$34.03M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CNTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.24M$2.44M$2.33M$1.96M$1.89M$1.93M$2.07M$1.79M
Research and development$5.72M$12.53M$7.02M$11.84M$8.72M$7.83M$3.46M$2.52M
Total operating expenses$7.96M$14.97M$9.34M$13.8M$10.61M$9.76M$5.53M$4.31M
Operating income-$7.96M-$14.97M-$9.34M-$13.8M-$10.61M-$9.76M-$5.53M-$4.31M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$7.62M-$14.56M-$8.68M-$13.03M-$9.69M-$8.83M-$4.58M-$3.34M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.62M-$14.56M-$8.68M-$13.03M-$9.69M-$8.83M-$4.58M-$3.34M
Net income attributable to common shareholders-$7.62M-$14.56M-$8.68M-$13.03M-$9.69M-$8.83M-$4.58M-$3.34M
EBITDA-$7.95M-$14.96M-$9.34M-$13.8M-$10.61M-$9.75M-$5.53M-$4.31M
Basic earnings per share-$0.08-$0.15-$0.09-$0.14-$0.10-$0.09-$0.05-$0.04
Diluted earnings per share-$0.08-$0.15-$0.09-$0.14-$0.10-$0.09-$0.05-$0.04

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

New Strong Sell Stocks for October 15th

Stock markets declined following a higher-than-expected CPI inflation report. Three companies were added to the Zacks Rank #5 (Strong Sell) list due to downward earnings estimate revisions: Cadiz Inc., Cerenome Inc., and Context Therapeutics Inc.

Zacks Investment Research

New Strong Sell Stocks for October 13th

Three companies have been added to the Zacks Rank #5 (Strong Sell) list due to significant downward revisions in earnings estimates over the past 60 days. ATS Corporation, an industrial automation company, saw a 6.7% downward revision. Cango Inc., a bitcoin mining company, experienced an 18.2% downward revision. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, faced a 15% downward revision.

Benzinga

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.